Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15529256 | 0.89 | CNR1 (0.50) | CNR1CNR2KMT2AEPHX2KDM4E | |
| SCHEMBL15528897 | 0.88 | ALDH1A1 (0.46) | CNR1CNR2EPHX2KDM4EALDH1A1 | |
| SCHEMBL15529072 | 0.87 | CNR1 (0.45) | CNR1CNR2KMT2AEPHX2KDM4E | |
| SCHEMBL16660101 | 0.85 | CNR1 (0.37) | CNR1CNR2EPHX2CHRNA7 | |
| SCHEMBL15529492 | 0.85 | CNR1 (0.37) | CNR1CNR2EPHX2CHRNA7 | |
| SCHEMBL16660100 | 0.82 | CNR1 (0.44) | CNR1CNR2EPHX2CYP2C9KDM4E | |
| SCHEMBL15529125 | 0.82 | CNR1 (0.44) | CNR1CNR2EPHX2CYP2C9KDM4E | |
| SCHEMBL15529045 | 0.81 | GAA (0.47) | CNR1CNR2KMT2AKDM4EALDH1A1 | |
| SCHEMBL15529491 | 0.81 | CNR1 (0.40) | CNR1CNR2KMT2AEPHX2KDM4E | |
| SCHEMBL15528874 | 0.80 | CNR1 (0.40) | CNR1CNR2KMT2AEPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-9409898-B2 | Substituted pyrazole compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-9409898-B2 | Substituted pyrazole compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| EP-2844656-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013164773-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | CNR1 194/4885CNR2 181/4885SCN9A 258/4885 |
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | CNR1 194/4885CNR2 181/4885SCN9A 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.